Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Brain-specific angiogenesis inhibitor 1 (BAI1) is a transmembrane protein with anti-angiogenic activity.
Interaction of brain-specific angiogenesis inhibitor 1 with bacteria triggers pro-inflammatory responses
The emerging role of BAI1 as a potential pattern recognition receptor (PRR) for Gram-negative bacteria has caused a special interest in BAI family members for their innate immunity and inflammation. Studies involving BAI1 depleted macrophages showed abnormally reduced levels of tumor necrosis factor production when stimulated by LPS or Gram-negative bacteria, suggesting that BAI1 may have a significant contribution in pro-inflammatory responses. Activities of BAI1 associated with detection of a key PAMP like LPS seemingly suggest its probable role in pro-inflammatory response similar to pattern recognition receptors (PRRs)–induced inflammation. This pro-inflammatory response plays a key role in the early detection of Gram-negative pathogens, immune activation and clearance, and subsequently aids adaptive immunity, and LPS is a major virulence factor for many types of gram-negative pathogens.
Currently, in macrophages and dendritic cells, Toll-like receptor (TLR)-4 is primarily responsible for the detection of bacterial LPS that triggers pro-inflammatory cytokine production and other inflammatory immune responses. In these cells, TLR-4 and co-receptors MD2 and CD14 can detect lipids. Interestingly, it has been found that the BAI1 TSRs can recognize and directly interact with LPS, which can internalization of gram-negative pathogen. A recent study showed that BAI1 is involved in the phagocytic uptake of Gram-negative bacteria as a PRR, and promotes the activation of NADPH oxidase activity in macrophages by activating the Rho1-dependent pathway of the Rho family GTPase, promoting phagosome reactive oxygen species. The authors have implemented a peritoneal infection model involving BAI1-deficient mice to demonstrate the novel properties of BAI1 in coupling bacterial assays to cell sterilization machinery. However, the underlying role of BAI1 as a PRR and the underlying mechanism of potential crosstalk between BAI1 and TLR4 is unclear.
Brain-specific angiogenesis inhibitor 1 and tumorigenesis
Abnormal expression of BAI1 protein is associated with the development of several malignancies. Significant down-regulation of BAI1 mRNA levels was observed in lung adenocarcinoma, primary glioma specimens, and advanced brain tumors. Studies on normal bladder mucosal biopsy specimens of bladder transitional cell carcinoma indicate that BAI1 is a negative regulator of microvascular proliferation with decreased BAI1 expression in progressive cancer samples.
In contrast, exogenous recovery of BAI1 expression has been reported to reduce tumor proliferation and angiogenesis associated with glioma and renal cancer. Many studies have shown that BAI1 expression is absent, defective or highly reduced in most human glioma cell lines and primary glioblastoma samples, thereby inhibiting its anti-tumorigenic activity. Changes in the p53 gene are associated with angiogenesis, a key step for glioma to enter glioblastoma. Although P53 is an important member of the tumor suppressor gene family, it is the most common mutated gene in human cancers. It was found that the expression of wild-type p53 mediated by adenovirus transfection can reconstitute the loss of BAI1 expression in a series of human cancer cell lines. Zhu et al, demonstrated that BAI1 regulates the normal development of cerebellum and prevents the transformation of neural progenitor cells during EGL amplification. BAI1 plays a suppressor tumor in MB, and it is an upstream protector of p53. Reveal that alteration in ADGRB1/BAI1 represents a point of vulnerability in cancer. BAI1 as a protective agent for p53 tumor suppressor, which is consistent with previous studies, the loss of p53 increased penetrance and accelerated tumor formation in the mouse MB model. BAI1 protects p53 by binding Mdm2, the p53 E3 ubiquitin ligase, thereby reduces its nuclear level and stabilizes p53. Taken together, these results define the BAI1-P53 signal axis and show its importance in brain tumorigenesis. Although most of the MB lacks the p53 mutation, approximately 40% of the macroblocks exhibit dysfunctional p53 target gene expression, suggesting that other mechanisms can abolish the tumor monitoring activity of p53.
Fig. 1. BAI1 inhibits tumorigenesis by preventing p53 from Mdm2-Mediated Degradation. (Zhu et al., 2018, Cancer Cell).
BAI1 as an engulfment receptor for apoptotic cells
BAI1 is increasingly recognized for its role in the phagocytosis of apoptotic cells which is mainly mediated by ELMO1/Dock/Rac1 signaling module. The ELMO1/Dock pathway finally leads to activation of small GTPase Rac proteins. The activity of Rac is critical for rapid actin remodeling and membrane trafficking during phagocytosis of apoptotic cells. The BAI1 receptor has also been identified as activating cytoskeletal recombination, involving the Rho pathway activated by Gα-dependent mechanisms. It is known that Helicobacter pylori or camptothecin induces apoptosis in gastric epithelial cells. A recent study showed a significant increase in BAI1 expression in peripheral blood mononuclear cell-derived macrophages or THP-1 cells, which is associated with increased binding and clearance of apoptotic epithelial cells by these gastric phagocytic cells. Previous studies have shown that the dual function of BAI1 as an apoptotic phagocytic receptor and an anti-angiogenic factor is based on their origin. In general, glial-derived BAI1 can be used for phagocytic function in adult brain regions (e.g., olfactory bulbs, which typically have high apoptotic turnover), and facial neuron-derived BAI1 acts as an anti-angiogenic factor in mature neuropil. Generally, macrophages are known to uptake large amounts of cholesterol during the removal of apoptotic cells. BAI1 has recently been associated with upregulation of ATP-binding cassette transporters (ABAC1), a vital protein for cholesterol efflux in macrophages. This suggests an important role for BAI1 in the membrane initiation pathway triggered by apoptotic cells.
Fig. 2. BAI1 as the receptor upstream of the ELMO1/Dock180/Rac1 module. (Penberthy et al. Immunol Rev. 2016)
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.